Маниге Кониг

1.2k total citations · 2 hit papers
34 papers, 867 citations indexed

About

Маниге Кониг is a scholar working on Endocrinology, Diabetes and Metabolism, Molecular Biology and Surgery. According to data from OpenAlex, Маниге Кониг has authored 34 papers receiving a total of 867 indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Endocrinology, Diabetes and Metabolism, 14 papers in Molecular Biology and 8 papers in Surgery. Recurrent topics in Маниге Кониг's work include Diabetes Treatment and Management (23 papers), Metabolism, Diabetes, and Cancer (13 papers) and Diabetes Management and Research (7 papers). Маниге Кониг is often cited by papers focused on Diabetes Treatment and Management (23 papers), Metabolism, Diabetes, and Cancer (13 papers) and Diabetes Management and Research (7 papers). Маниге Кониг collaborates with scholars based in United States, Germany and Canada. Маниге Кониг's co-authors include Sohini Raha, Reema Mody, Edward Pratt, Deborah A. Robins, Xiaosu Ma, Kieren J. Mather, Axel Haupt, Christof Kazda, Sean Wharton and Rong Liu and has published in prestigious journals such as New England Journal of Medicine, The Lancet and The Journal of Clinical Endocrinology & Metabolism.

In The Last Decade

Маниге Кониг

32 papers receiving 853 citations

Hit Papers

Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults... 2023 2026 2024 2025 2023 2023 50 100 150 200 250
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity
    2023 259 citations Sean Wharton, Thomas Blevins et al. New England Journal of Medicine profile →
  2. Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study
    2023 97 citations Juan P. Frías, Stanley H. Hsia et al. The Lancet profile →

Peers

Маниге Кониг
V. Pechtner United States
Dominik Dahl Germany
Toshihiko Shiraiwa Japan
Shingo Takahara Japan
P. Damsbo Denmark
Kazutaka Aoki Japan
Hiren Patel United States
Mette Marie Hougaard Christensen Denmark
Fady T. Botros United States
V. Pechtner United States
Маниге Кониг
Citations per year, relative to Маниге Кониг Маниге Кониг (= 1×) peers V. Pechtner

Countries citing papers authored by Маниге Кониг

Since Specialization
Citations

This map shows the geographic impact of Маниге Кониг's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Маниге Кониг with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Маниге Кониг more than expected).

Fields of papers citing papers by Маниге Кониг

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Маниге Кониг. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Маниге Кониг. The network helps show where Маниге Кониг may publish in the future.

Co-authorship network of co-authors of Маниге Кониг

This figure shows the co-authorship network connecting the top 25 collaborators of Маниге Кониг. A scholar is included among the top collaborators of Маниге Кониг based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Маниге Кониг. Маниге Кониг is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Thompson, Brian R., Bram Brouwers, Hui-Rong Qian, et al.. (2025). LY3522348, A New Ketohexokinase Inhibitor: A First-in-Human Study in Healthy Adults. Diabetes Therapy. 16(7). 1399–1415. 1 indexed citations
2.
Rosenstock, Julio, Deborah A. Robins, Kevin L. Duffin, et al.. (2025). Orforglipron, an oral non‐peptide glucagon‐like peptide‐1 receptor agonist, improves markers of β‐cell function and insulin sensitivity in type 2 diabetes. Diabetes Obesity and Metabolism. 27(11). 6314–6322. 1 indexed citations
3.
4.
Franek, Edward, Prem Pais, Jan Basile, et al.. (2023). General versus central adiposity as risk factors for cardiovascular-related outcomes in a high-risk population with type 2 diabetes: a post hoc analysis of the REWIND trial. Cardiovascular Diabetology. 22(1). 52–52. 16 indexed citations
5.
Lim, Jean K., et al.. (2023). Practical Applications of a Nausea and Vomiting Model in the Clinical Development of Additional Doses of Dulaglutide. The Journal of Clinical Pharmacology. 64(2). 215–226. 1 indexed citations
6.
Frías, Juan P., Stanley H. Hsia, Rong Liu, et al.. (2023). Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study. The Lancet. 402(10400). 472–483. 97 indexed citations breakdown →
7.
Wharton, Sean, Thomas Blevins, Lisa Connery, et al.. (2023). Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity. New England Journal of Medicine. 389(10). 877–888. 259 indexed citations breakdown →
8.
9.
Van, Joanna, Juan P. Frías, Enzo Bonora, et al.. (2021). Gastrointestinal Tolerability of Once-Weekly Dulaglutide 3.0 mg and 4.5 mg: A Post Hoc Analysis of the Incidence and Prevalence of Nausea, Vomiting, and Diarrhea in AWARD-11. Diabetes Therapy. 12(10). 2783–2794. 11 indexed citations
10.
Кониг, Маниге, Matthew C. Riddle, Helen M. Colhoun, et al.. (2021). Exploring potential mediators of the cardiovascular benefit of dulaglutide in type 2 diabetes patients in REWIND. Cardiovascular Diabetology. 20(1). 194–194. 42 indexed citations
11.
12.
Frías, Juan P., Enzo Bonora, Luis Nevárez Ruiz, et al.. (2021). Efficacy and safety of dulaglutide 3.0 and 4.5 mg in patients aged younger than 65 and 65 years or older: Post hoc analysis of the AWARD ‐11 trial. Diabetes Obesity and Metabolism. 23(10). 2279–2288. 7 indexed citations
13.
Robinson, Susan, Kristina S. Boye, Reema Mody, et al.. (2020). Real-World Effectiveness of Dulaglutide in Patients with Type 2 Diabetes Mellitus: A Literature Review. Diabetes Therapy. 11(7). 1437–1466. 18 indexed citations
14.
Patel, Hiren, et al.. (2019). Efficacy of Dulaglutide as a First Injectable Option for Patients with Type 2 Diabetes: A Post-Hoc Pooled Analysis. Diabetes Therapy. 10(6). 2321–2330. 7 indexed citations
15.
Streeten, Elizabeth A., et al.. (2017). Hypoparathyroidism: Less Severe Hypocalcemia With Treatment With Vitamin D2 Compared With Calcitriol. The Journal of Clinical Endocrinology & Metabolism. 102(5). 1505–1510. 17 indexed citations
16.
Кониг, Маниге, et al.. (2013). An Insight into the Recent Diabetes Trials: What is the Best Approach to Prevent Macrovascular and Microvascular Complications?. Current Diabetes Reviews. 9(5). 371–381. 35 indexed citations
17.
Wang, Hong, Urmila Sreenivasan, Da‐Wei Gong, et al.. (2013). Cardiomyocyte-specific perilipin 5 overexpression leads to myocardial steatosis and modest cardiac dysfunction. Journal of Lipid Research. 54(4). 953–965. 114 indexed citations
18.
Кониг, Маниге & Alan R. Shuldiner. (2011). The genetic interface between gestational diabetes and type 2 diabetes. The Journal of Maternal-Fetal & Neonatal Medicine. 25(1). 36–40. 19 indexed citations
19.
Nauck, Matthias, Maria Stella Graziani, Jochen Jarausch, et al.. (1999). A New Liquid Homogeneous Assay for HDL Cholesterol Determination Evaluated in Seven Laboratories in Europe and the United States. Clinical Chemistry and Laboratory Medicine (CCLM). 37(11-12). 1067–1076. 12 indexed citations
20.
Vogelberg, K. H., P. Mayer, & Маниге Кониг. (1990). Decrease of macrovascular hyperemic response of blood flow in diabetics with arterial neuropathy. Journal of Molecular Medicine. 68(12). 588–593. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by V. Pechtner Breakdown of academic impact, for papers by Dominik Dahl Breakdown of academic impact, for papers by Toshihiko Shiraiwa Breakdown of academic impact, for papers by Shingo Takahara Breakdown of academic impact, for papers by P. Damsbo Breakdown of academic impact, for papers by Kazutaka Aoki Breakdown of academic impact, for papers by Hiren Patel Breakdown of academic impact, for papers by Mette Marie Hougaard Christensen Breakdown of academic impact, for papers by Fady T. Botros
Rankless by CCL
2026